Financial Performance - Fourth quarter 2024 GAAP revenue was $729 million, representing a 5% increase year-over-year, with organic growth of 6%[3][4][8] - Fourth quarter 2024 adjusted earnings per share from continuing operations was $1.42, compared to $1.25 in the same period last year[4][8] - Full year 2024 GAAP revenue was $2,755 million, slightly up from $2,751 million in 2023[5][6] - Full year 2024 adjusted earnings per share from continuing operations was $4.90, an increase from $4.65 in 2023[6] - The company reported a net income of $94.6 million for the fourth quarter 2024, compared to $78.6 million in the same period last year[21] - Net income for the three months ended December 29, 2024, was $94,645,000, compared to $78,563,000 for the same period in 2023, representing a year-over-year increase of 20.5%[29] - Income from continuing operations for the twelve months ended December 29, 2024, was $283,071,000, up from $179,503,000 in 2023, reflecting a growth of 57.7%[29] Operating Income and Margins - Fourth quarter 2024 GAAP operating income from continuing operations was $119 million, up from $77 million in the same period last year[3][4] - Full year 2024 GAAP operating profit margin from continuing operations was 12.6%, compared to 10.9% in 2023[5] - Fourth quarter 2024 adjusted operating income was $221 million, compared to $192 million in the same period last year[4] - Reported operating income from continuing operations for the twelve months ended December 29, 2024, was $346,741 thousand, compared to $300,562 thousand for the same period in 2023, an increase of about 15%[24] - Operating margin (OP%) improved to 30.3% in Q4 2024 from 27.5% in Q4 2023[24] Revenue by Segment - Life Sciences segment revenue for Q4 2024 was $336,340 thousand, up from $319,691 thousand in Q4 2023, representing a growth of approximately 5.3%[24] - Diagnostics segment revenue for Q4 2024 was $393,240 thousand, an increase from $376,419 thousand in Q4 2023, reflecting a growth of about 4.5%[24] - The company reported a 5% organic revenue growth in the Life Sciences segment for the three months ended December 29, 2024[31] - The Diagnostics segment achieved an organic revenue growth of 4% for the three months ended December 29, 2024, despite a 1% negative impact from foreign exchange rates[31] Guidance and Future Outlook - The company initiated full year 2025 guidance, forecasting total revenue of $2.80-$2.85 billion and adjusted earnings per share of $4.90-$5.00[11][12] - The company plans to continue focusing on operational efficiency and strategic investments to drive future growth[33] Cash Flow and Assets - The company reported a net cash provided by operating activities of continuing operations of $664,955,000 for the twelve months ended December 29, 2024, compared to $279,387,000 in 2023, indicating a significant increase of 138.4%[29] - Cash, cash equivalents, and restricted cash at the end of the period were $1,164,452,000, an increase from $914,373,000 at the end of the previous year[30] - Total current assets decreased to $2,349,608 thousand in Q4 2024 from $3,001,091 thousand in Q4 2023, a decline of approximately 22%[26] - Cash and cash equivalents increased to $1,163,396 thousand in Q4 2024 from $913,163 thousand in Q4 2023, showing a growth of about 27%[26] - The company experienced a net cash used in financing activities of continuing operations amounting to $1,128,235,000 for the twelve months ended December 29, 2024, compared to $947,121,000 in 2023[30] Non-GAAP Measures - The company uses "adjusted operating income" to refer to GAAP operating income, which includes revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules[40] - "Free cash flow" is defined as net cash provided by operating activities of continuing operations, less capital expenditures, plus proceeds from capital disposals[41] - "Adjusted net income" excludes various costs such as amortization of intangible assets and significant litigation matters, reflecting a more accurate performance of ongoing operations[42] - "Adjusted earnings per share" from continuing operations is calculated by excluding costs related to debt extinguishment and asset impairments, among others[43] - Management excludes amortization of intangible assets from non-GAAP measures as it does not reflect ongoing operational performance[44] - Significant expenses related to acquisitions and divestitures are excluded from non-GAAP measures to provide a clearer view of operational performance[45] - The company does not consider asset impairments and restructuring charges as reflective of ongoing operations, thus excluding them from adjusted measures[46] - Non-GAAP financial measures are not considered superior to GAAP financial statements and should be viewed in conjunction with them[47] - These non-GAAP measures are used by management to evaluate operating performance and benchmark results against peers[48]

Revvity, Inc. (RVTY) is slated to report fourth-quarter 2024 results on Jan. 31, before market open.In the last reported quarter, the company delivered an earnings surprise of 13.27%. RVTY’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.55%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $730.1 million, up 4.9% from the prior-year quarter’s level. The consensus mar ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Revvity (RVTY) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 31, 2025, might help the stock move higher if these key numbers are better than expe ...

Company Overview - Revvity has a market capitalization of $13.86 billion with an earnings yield of 4.4%, which is favorable compared to the industry's 3.7% [1] - The company delivered an earnings surprise of 13.3% in the last reported quarter [1] FDA Approval and Product Development - Revvity received FDA 510(k) clearance for EUROIMMUN's automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone, making it the only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma [2] - The assay is processed on Revvity's random-access iSYS or i10 instruments, offering quick turnaround times, high-throughput testing, minimal technician training, and high accuracy [4] - The assay is expected to enhance diagnostic capabilities for conditions like hypogonadism and impotence by providing direct measurement of free testosterone levels in a single test [4] - Management believes the FDA clearance will expand the FDA-cleared menu for EUROIMMUN's ChLIA automation solutions, serving a diverse patient pool across all demographics [5] - Results on EUROIMMUN's ChLIA platforms are expected to be rapidly available, with the first result available in 48 minutes and an estimated throughput of nearly 60 tests per hour [15] Market and Industry Prospects - The global testosterone test market was valued at $100 million in 2023 and is anticipated to reach $208.1 million by 2034, growing at a CAGR of 6.9% [6] - Factors driving the market include rising awareness about hormonal disorders and increasing prevalence of male infertility [6] - The latest FDA clearance is expected to be a significant milestone for Revvity, boosting its business in this growing market [6] Recent Developments - In November 2024, Revvity expanded its collaboration with Genomics England to advance critical genomic initiatives across the UK [7] - The company reported solid revenue growth in its third-quarter 2024 results, both on a reported and organic basis [7] Stock Performance - Following the FDA approval announcement, Revvity's shares lost nearly 2.2% by Friday's closing [3] - Historically, the company has gained a top-line boost from regulatory achievements and product launches, but the stock declined overall despite the latest FDA approval [3] - Over the past year, Revvity's shares have gained 2.8%, outperforming the industry's 9.8% decline, while the S&P 500 gained 23% [9] Comparison with Industry Peers - Cardinal Health (CAH) has a Zacks Rank 2 (Buy) with an estimated long-term growth rate of 10.5% and an average earnings surprise of 11.2% over the trailing four quarters [11] - ResMed (RMD) has a Zacks Rank 2 with an estimated long-term growth rate of 14.8% and an average earnings surprise of 6.4% over the trailing four quarters [12] - Boston Scientific (BSX) has a Zacks Rank 2 with an estimated long-term growth rate of 13.8% and an average earnings surprise of 8.3% over the trailing four quarters [12] - Cardinal Health's shares have gained 14.9% compared to the industry's 2.1% growth, ResMed has gained 34.5% compared to the industry's 7.8% growth, and Boston Scientific has rallied 58.3% compared to the industry's 7.8% growth over the past year [11][12][13]

Revvity, Inc. (NYSE: RVTY ) is clearly a leader in life sciences and diagnostics. Both of these revenue verticals provide cutting-edge tools and platforms for drug discovery and development, as well as early detection of genetic and infectious conditions. The company has a globalMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, U ...

It has been about a month since the last earnings report for Revvity (RVTY) . Shares have lost about 8.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Revvity due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. RVTY Q3 Earnings & Revenues Beat Estimates, Guidance R ...

Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday.The company posted quarterly earnings of $1.28 per share which beat the analyst consensus estimate of $1.13 per share. The company reported quarterly sales of $684.05 million which beat the analyst consensus estimate of $679.65 million.Revvity also authorized a new $1 billion share repurchase program.“We performed well during the third quarter with a return to positive revenue growth, strong margins, and another period of exce ...

Revvity, Inc. (RVTY) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.28, which beat the Zacks Consensus Estimate of $1.13 by 13.3%. The bottom line improved 8.5% from the year-ago quarter’s level.GAAP EPS from continuing operations was 76 cents compared with 26 cents in the prior-year period. However, GAAP EPS in the reported quarter was 77 cents, which includes a loss of 1 cent per share from discontinued operations.Revenue DetailsBased in Waltham, MA, this leading MedTech company repor ...

Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.27%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.13 per share when it actually produced earnings of $1.22, delivering a surprise of 7.96%.Over the last four quarter ...

Revvity, Inc. (RVTY) announced the launch of the in-vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark on Oct. 2. The assay will likely enable accurate genotyping of the APOE gene. It is worth mentioning that APOE genotyping allows the assessment of a patient's risk for side effects before the start of an anti-amyloid (beta) therapy in Alzheimer's disease (AD). The latest launch in European countries that accept the CE mark is expected to significantly boost Revvity's EUR ...